AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24881917
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment in international study (both MTX1 and MTX3 arms)
Trial: 22552038
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg vitamin D3 daily for 10 weeks
Trial: 22552038
Drug: 7 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 μg 25-hydroxyvitamin D3 daily for 10 weeks
Trial: 22552038
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg 25-hydroxyvitamin D3 daily for 10 weeks
Trial: 17388752
Drug: Cyproheptadine hydrochloride
RxNorm normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine hydrochloride (CH) 2 mg QID for 1 week followed by 4 mg QID for 11 weeks
Trial: 15576390
Drug: rLH supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH supplementation (150 IU) in addition to rFSH (225 IU starting dose)
Trial: 15576390
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal responders with rFSH monotherapy)
Trial: 9466083
Drug: Metronidazole 1
RxNorm normalized name: metronidazole 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1 percent cream applied once daily
Trial: 8595079
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with liposomal gel formulation containing 2% tetracaine
Trial: 8595079
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro drug liberation
Trial: 1974941
Drug: Methylfolate, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylfolate, 15 mg daily for 6 months in addition to standard psychotropic treatment
Trial: 30003324
Drug: Ibuprofen gel
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen gel phonophoresis
Trial: 30003324
Drug: Ibuprofen cream
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen cream phonophoresis
Trial: 26582047
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg at induction, followed by 0.25 mg/kg/h continuous infusion for 30 min)
Trial: 26582047
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% saline, 0.05 ml/kg at induction, followed by 0.025 ml/kg/h continuous infusion for 30 min)
Trial: 22997792
Drug: Acupotomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy treatment once a week for 3 weeks.
Trial: 22997792
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment 3 times a week for 3 weeks.
Trial: 20332722
Drug: Conventional neuro-rehabilitation
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) plus 60 minutes of mental practice training for 3 weeks
Trial: 20332722
Drug: Conventional neuro-rehabilitation
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) for 3 weeks
Trial: 10077172
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with recombinant interferon-alpha2b (rIFN-alpha2b) and zidovudine (ZDV)
Trial: 6938242
Drug: New drug
RxNorm normalized name: varicella zoster immune globulin (Investigational New Drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drug combination (cincain chloride, tri‐iodomethane, tranexamic acid, propyl‐hydroxy‐benzoic acid in Gelfoam)
Trial: 26189808
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (rotator cuff repair)
Trial: 26189808
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (rotator cuff repair) without retear
Trial: 21057805
Drug: Ranibizumab-based therapy
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab-based therapy
Trial: 19054783
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day soy isoflavones
Trial: 15539961
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg q x d)
Trial: 1888695
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg once daily)
Trial: 1758250
Drug: IG/IH nerve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IG/IH nerve block (0.25% bupivacaine, 1 mg/kg)
Trial: 1758250
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 microgram/kg)
Trial: 7117428
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and inhalation salbutamol
Trial: 7117428
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (oral and inhalation)
Trial: 30659063
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) plus asthma education
Trial: 25181946
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg prednisolone per day, tapered to 5 mg over 8 weeks
Trial: 25181946
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisolone per day, tapered to 5 mg over 8 weeks
Trial: 25181946
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg prednisolone per day
Trial: 25181946
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisolone per day
Trial: 22909076
Drug: self‐administered relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered relaxation acupressure
Trial: 22909076
Drug: self‐administered stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered stimulating acupressure
Trial: 18946667
Drug: Lemon juice
RxNorm normalized name: lemon juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemon juice (60 mEq/day, approximately 85 cc/day)
Trial: 11802748
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment with 3 antibiotics (amoxicillin 1 g bid, clarithromycin 250 mg bid, metronidazole 400 mg bid) and lansoprazole 30 mg bid (L5)
Trial: 11802748
Drug: 3-day antibiotic-lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day antibiotic-lansoprazole combination (L3) with a 2-day pretreatment with lansoprazole
Trial: 11802748
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment with 3 antibiotics and ranitidine hydrochloride 300 mg bid (R5)
Trial: 10621929
Drug: Herbal remedy
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujae), 3 tablets t.i.d. for 7 to 9 days
Trial: 8565486
Drug: Empty patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty patch
Trial: 6874890
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone enanthate
Trial: 6874890
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg testosterone enanthate
Trial: 31072850
Drug: Stretching/flexibility exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching/flexibility exercise programme combined with placebo supplements
Trial: 29863974
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of cyclophosphamide
Trial: 23281754
Drug: D, L-propargylglycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D, L-propargylglycerine (CSE inhibitor)
Trial: 14760111
Drug: Exemestane (E)
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane (E) 25 mg once daily
Trial: 14760111
Drug: Tamoxifen (T)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (T) 20 mg once daily
Trial: 11142488
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (VER) 240 mg/day divided in 2 doses, from day 1 to day 28 of each cycle
Trial: 9187418
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg/day starting at day 3, increasing to 20 mg/day for 3 months
Trial: 22160628
Drug: Standard Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Support Therapy (SST)
Trial: 20642391
Drug: Atomoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine treatment at Week 8
Trial: 20642391
Drug: Atomoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine treatment at 40 weeks
Trial: 20642391
Drug: Atomoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine treatment at 8 weeks
Trial: 17977190
Drug: Platelet gel
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet gel treatment
Trial: 17977190
Drug: No platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No platelet gel treatment (Control)
Trial: 9535315
Drug: Carbamazepine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (450 mg at 150 mg three times per day, increased as needed)
Trial: 9535315
Drug: Carbamazepine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (after stopping, lactose placebo administered for 3 weeks)
Trial: 9535315
Drug: Carbamazepine (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (second treatment)
Trial: 1106746
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rimiterol and terbutaline
Trial: 26846795
Drug: Dextrose injections
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose injections
Trial: 19700470
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/day followed by 300 mg/day on day 15
Trial: 19700470
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg/day followed by 20 mg/day on day 15
Trial: 17479947
Drug: Atazanavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (400 mg per day or 300/100 mg per day with ritonavir)
Trial: 15543343
Drug: Cerivastatin 0.2
RxNorm normalized name: cerivastatin 0.2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.2 mg to 0.4 mg daily for 12 weeks
Trial: 15543343
Drug: Fenofibrate 250
RxNorm normalized name: fenofibrate 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 250 mg daily for 12 weeks
Trial: 12867500
Drug: Intracutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injection of endogenous PAR‐2 agonists
Trial: 12867500
Drug: Local antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antihistamines
Trial: 10230458
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy before irradiation
Trial: 10230458
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy after irradiation
Trial: 10230458
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with a gap between treatment fields
Trial: 6294770
Drug: Post-cardiac arrest
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-cardiac arrest thiopental loading (30 mg/kg body wt)
Trial: 24509407
Drug: High-dose interferon-alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha2b (HDI) plus GM2-KLH/QS-1 (GMK)
Trial: 24509407
Drug: High-dose interferon-alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha2b (HDI)
Trial: 24509407
Drug: GMK (vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMK (vaccine group)
Trial: 19171716
Drug: Continuing chemotherapy/cis-RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing chemotherapy/cis-RA
Trial: 19171716
Drug: Chemotherapy/no cis-RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/no cis-RA
Trial: 15002538
Drug: L-arginine-hydrochloride (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine-hydrochloride (18 g)
Trial: 3315761
Drug: Hypoglycaemia induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia induced by insulin-glucose clamp technique (insulin: 2.4 mU/kg/min + glucose at variable rate) after an overnight fast
Trial: 3315761
Drug: Hypoglycaemia induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia induced by insulin-glucose clamp technique after 72 hours fasting
Trial: 27345636
Drug: Bendamustine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine monotherapy
Trial: 22419151
Drug: Acarbose test
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose test formulation (2×50 mg)
Trial: 17766766
Drug: Standard, therapist-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, therapist-led group therapy
Trial: 15150679
Drug: Dexamethasone (DEXA)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEXA) 2.0 mg
Trial: 15150679
Drug: Prednisolone (PRED)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (PRED) 12.5 mg
Trial: 1562888
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (distensive and nondistensive)
Trial: 354827
Drug: alpha-methyldopa up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-methyldopa up to 500 mg b.i.d.
Trial: 354827
Drug: metoprolol up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol up to 200 mg b.i.d.
Trial: 20821373
Drug: PST-OT (Problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST-OT (Problem-solving and Occupational Therapy intervention)
Trial: 11355097
Drug: 0.1% fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluoride varnish application and professional tooth-cleaning, motivation and instruction in oral hygiene (T)
Trial: 11355097
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction and supervised toothbrushing once a year (C)
Trial: 25467826
Drug: 10-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day standard sequential therapy
Trial: 25467826
Drug: levofloxacin-containing sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levofloxacin-containing sequential therapy
Trial: 16938120
Drug: Patient self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-management (PSM) of anticoagulation therapy
Trial: 9950107
Drug: Amoxicillin/clavulanate (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (625 mg every 8 hours for 10 days)
Trial: 7567310
Drug: Ceftibuten (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (9 mg/kg daily for 10 days)
Trial: 7567310
Drug: Amoxicillin/clavulanate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (40 mg/kg/day given every 8 hours for 10 days)
Trial: 6996138
Drug: Standardized senna
RxNorm normalized name: standardized senna concentrate
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized senna tablets (Senokot; Reckitt & Colman)
Trial: 14695410
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of sucrose
Trial: 27125669
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4 mg/m2 as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle
Trial: 24336820
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole (CMX) 800 mg/160 mg
Trial: 24336820
Drug: Sulfadoxine-pyrimethamine intermittent
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)
Trial: 24336820
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole (CMX)
Trial: 12017952
Drug: Intermittent epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent epidural analgesia with bupivacaine plus intravenous Ketorolaco
Trial: 6993548
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of CB-154 (5 mg po) one hour before arginine test
Trial: 27872117
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (neoadjuvant long course radiotherapy ± chemotherapy and APER)
Trial: 24560173
Drug: DFDBA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFDBA plus lincomycin therapy
Trial: 22133470
Drug: Beta-blocker up-titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker up-titration to 12.5% of target dose
Trial: 22133470
Drug: Beta-blocker up-titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker up-titration to 25% of target dose
Trial: 22133470
Drug: Beta-blocker up-titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker up-titration to 50% of target dose
Trial: 22133470
Drug: Beta-blocker up-titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker up-titration to 100% of target dose
Trial: 22133470
Drug: Groups 3/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 3/4 (50% and 100% target dose)
Trial: 22133470
Drug: Groups 1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 1/2 (12.5% and 25% target dose)
Trial: 17959943
Drug: Greek tsatsiki
RxNorm normalized name: Greek pitch
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greek tsatsiki with 4.2 g raw garlic (verum)
Trial: 17959943
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of 4.2 g of raw garlic over 1 week
Trial: 16296439
Drug: One‐Step (one‐bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One‐Step (one‐bottle bonding agent)
Trial: 16296439
Drug: Gluma Desensitizer
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gluma Desensitizer (glutaraldehyde‐based agent)
Trial: 10217550
Drug: 21 mg/day
RxNorm normalized name: nicotine 21 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg/day transdermal nicotine patch (Nicoderm CQ)
Trial: 6381610
Drug: HuIFN‐alpha 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuIFN‐alpha 2 nasal spray (9 X 10(6) international units, three times a day for five days)
Trial: 23622801
Drug: 14-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day quadruple therapy (OMAB group) comprising omeprazole 20mg, metronidazole 500 mg, amoxicillin 1g, and bismuth subcitrate 240 mg
Trial: 23622801
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple regimen (OCP group) comprising omeprazole 20mg plus clarithromycin 500 mg and penbactam 750 mg
Trial: 23622801
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple regimen (OCA group) comprising omeprazole 20mg plus clarithromycin 500 mg and amoxicillin 1g
Trial: 12869883
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 28 days